# MOTS-c: Energy Balance at the Cellular Level > MOTS-c: Research Overview — Metabolic & Weight Research Peptides — Desert Peptides — A briefing on MOTS-c, the mitochondrial-derived peptide studied at the cellular end of energy balance: AMPK activation, muscle glucose uptake, exercise induction, and the human evidence that does not yet exist. **01 / METABOLIC & WEIGHT RESEARCH** A peptide encoded inside the mitochondrial genome, studied for how muscle handles fuel. Strong mechanism, animal performance data, and no completed human efficacy trial. ## The short version MOTS-c is a very short peptide — sixteen amino acids — that the body makes from a gene inside the *mitochondria*, the compartments in a cell that turn food into usable energy [3]. Almost every other human peptide is written in the cell's nucleus, so a peptide with a mitochondrial return address is unusual on its own. Its best-studied job is to make skeletal muscle handle glucose better. It switches on an enzyme called AMPK, which cells use as a low-fuel alarm: when AMPK is active, muscle pulls in more glucose and burns more fuel rather than storing it. Exercise raises the body's own MOTS-c levels, which is why it is sometimes described in the literature as an exercise-mimetic signal [4]. What matters most on this page is what is missing. No completed human trial has tested whether giving MOTS-c to a person changes body weight, body composition or fitness. The human data are observational — measurements of naturally circulating MOTS-c and what they track with — and everything else is cell and animal work. It is not approved for human use anywhere, and no dose or schedule for a person is described here. ## What it is MOTS-c stands for *mitochondrial open reading frame of the 12S rRNA type-c*. It is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame sitting inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1) — part of the small circular genome the mitochondrion carries separately from the cell nucleus. The sequence is highly conserved across mammalian species, which is generally read as evidence of a load-bearing biological role rather than an accident of translation [3]. That places it in a class called mitochondrial-derived peptides: short peptides read out of mitochondrial DNA that act as signals to the rest of the cell and, in circulation, to the rest of the body. Classification matters here for a practical reason. MOTS-c is not a drug analogue built to improve on a hormone, the way the incretin peptides on this desk are; it is a naturally occurring signal being studied for what it does, with pharmacology as a downstream question that has not yet been answered in humans. Its regulatory position follows from that. MOTS-c has no FDA approval, no approved indication, no approved formulation and no established human dosing. It is sold only as a research chemical for laboratory use, and anti-doping bodies treat it as a prohibited substance in elite sport under hormone-and-metabolic-modulator categories. ## How it works The best-characterised mechanism runs through the folate cycle. MOTS-c inhibits the folate cycle and de novo purine biosynthesis, which causes AICAR to accumulate. AICAR is an endogenous activator of AMP-activated protein kinase (AMPK), the cell's central low-energy sensor, and the resulting AMPK activation improves glucose handling and insulin sensitivity, primarily in skeletal muscle [3]. A second mechanism is regulatory rather than metabolic. Under metabolic stress, MOTS-c translocates out of the mitochondrion and into the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner — including antioxidant-response-element genes through interaction with stress-responsive transcription factors such as NRF2 [5]. That was the first demonstration of retrograde signalling by a mitochondrial-encoded peptide: information travelling from the mitochondrion back to the nucleus, rather than the other way round. A 2024 study added a direct molecular target. MOTS-c binds and activates casein kinase 2 (CK2) in cell-free systems, and tissue-specific modulation of CK2 — activation in muscle, suppression in fat — was proposed as the mechanism behind its effects on muscle glucose uptake and on prevention of muscle atrophy [1]. Documented targets, in short: AMPK as the downstream effector; folate-cycle enzymes and de novo purine biosynthesis upstream of it; NRF2 and antioxidant-response-element genes in the nucleus; CK2 as a direct binding partner; and skeletal muscle as the primary target organ. ## What the research shows **The direct target (2024).** MOTS-c was shown to bind and activate CK2 directly in cell-free assays, identifying CK2 as a functional molecular target. In mice — young, aged, high-fat-diet and immobilised — tissue-specific CK2 modulation was linked to prevention of skeletal-muscle atrophy and to enhanced muscle glucose uptake [1]. **The strongest human data are associative (2024).** In a prospective multicentre cohort of 94 chronic haemodialysis patients followed for a median of 26.5 months, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and adding it to the risk model improved discrimination, with the ROC AUC moving from 0.727 to 0.743 [2]. This is among the strongest human clinical-association data for the peptide, and it is worth being precise about what it is: a biomarker association in a small, specific, seriously ill population. It says something about endogenous MOTS-c as a marker. It says nothing about administering MOTS-c as an intervention. **Exercise induction and animal performance (2021).** Exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation. Exogenous MOTS-c significantly increased treadmill running capacity (P=0.000002), grip strength and gait in mice, with the performance effect demonstrated across animals aged 2, 12 and 22 months and most striking in the aged 22-23.5-month group [4]. That study is the origin of the exercise-mimetic framing. **Retrograde signalling (2018).** The nuclear-translocation work in human and mouse cells established that a mitochondrial-encoded peptide can regulate nuclear gene expression under metabolic stress, in an AMPK-dependent manner [5]. **The orientation reference (2023).** A comprehensive review consolidated MOTS-c biology — its encoding within MT-RNR1, the AMPK and folate-cycle mechanism, nuclear translocation, exercise inducibility, and roles spanning metabolic, stress-adaptive and ageing pathways — and remains the standard entry point to the literature [3]. ## Reported effects, cautions & what is unknown This desk carries no structured set of community-reported effects for MOTS-c, and none is invented here. Where a compound on this site has a body of user-reported experience, it is rendered and labelled as anecdotal, not clinical evidence; for MOTS-c the honest entry is that the corpus behind this page does not hold one, so what follows is the documented caution list instead. **No human efficacy trials.** Every claim that exogenous MOTS-c improves metabolism, performance or ageing rests on cell or animal work, predominantly mice and rats. The human data are observational biomarker associations, not interventional outcomes. **No validated human pharmacokinetics.** There is no published, measured human half-life, bioavailability or dose-response for MOTS-c. Rodent dosing cannot be extrapolated to people, and this page does not restate rodent figures as if they were a starting point for anything. **Research-chemical status.** MOTS-c is not approved by the FDA for any use and is sold only for laboratory research. Purity, identity and sterility vary between suppliers and are not regulated to pharmaceutical standards. **Anti-doping prohibition.** MOTS-c is treated as a prohibited peptide in elite sport under hormone-and-metabolic-modulator categories, and athletes face sanctions for its use. **Replication and sample size.** Several human biomarker studies in this literature are small or preliminary, some mechanistic effects await independent replication, and a portion of the work comes from a small number of laboratories. **Genotype and ancestry interactions.** A pro-diabetogenic MOTS-c mitochondrial DNA variant (m.1382A>C) and ancestry-dependent exercise responses both suggest that effects are not uniform across populations — a complication that mechanism summaries tend to flatten. **The gap this page exists to mark.** Consumer interest in MOTS-c for fat loss, longevity and performance, and the search demand that comes with it, run well ahead of the strength of the clinical evidence. ## Where it fits in energy balance On the intake–expenditure–storage frame this desk uses, MOTS-c sits furthest from intake. Nothing in its documented mechanism suppresses appetite or slows gastric emptying. It acts on how a cell, and especially a muscle cell, handles the fuel it already has: AMPK activation, glucose uptake, substrate handling and stress-gene regulation [1][3][5]. That makes it conceptually adjacent to the expenditure side rather than a member of it. The animal performance data point toward improved capacity for work rather than toward a calorie deficit [4], and the human data currently available describe circulating MOTS-c as a marker that tracks with outcomes, not as an intervention that produces them [2]. Read alongside the incretin compounds on this desk, the contrast is instructive. [Semaglutide](/semaglutide) has hard clinical outcomes and a mechanism that acts above the cell, on the circuits that decide when a meal ends. [Retatrutide](/retatrutide) adds a glucagon arm that raises expenditure at the whole-body level. MOTS-c has the most interesting biology of the three and the least human evidence, and both halves of that sentence carry equal weight. The [side-by-side page](/compare) sets the three against each other on the dimensions that separate them. --- Desert Peptides reads the metabolic-peptide literature and reports what was measured, in the population it was measured in — a briefing desk, not a clinic, not a pharmacy, and not a source of advice.